- Page 1 and 2:
Guidelines forComplications ofCance
- Page 3:
Dedicated toAll our patients atThe
- Page 6 and 7:
Section IIHead & Neck 151Complicati
- Page 8 and 9:
PrefaceTreatment of cancer by vario
- Page 10:
Section — IGeneralContributorsDr.
- Page 13 and 14:
6. Complications after breast recon
- Page 15 and 16:
promises to reduce this risk of ser
- Page 17 and 18:
preceded by increased sensory hyper
- Page 19 and 20:
had significant lymphoedema. The fa
- Page 21 and 22: 2. Smoking as a risk factor for wou
- Page 23 and 24: 4. Preoperative core needle biopsy
- Page 25 and 26: eduction mammoplasty, and axillary-
- Page 27 and 28: postoperative wound infection follo
- Page 29 and 30: ablative surgical treatment for car
- Page 31 and 32: postoperative seroma formation usin
- Page 33 and 34: dressing consisted of a circumferen
- Page 35 and 36: mastectomies with axillary node cle
- Page 37 and 38: mastectomy for breast cancer. Early
- Page 39 and 40: monitored for the development of po
- Page 41 and 42: modality, and tumor stage distribut
- Page 43 and 44: 26. Pain and other symptoms during
- Page 45 and 46: 28. Coping, catastrophizing and chr
- Page 47 and 48: surgical technique at the time of m
- Page 49 and 50: 0.001), 0.315 cm +/- 1.27 at the an
- Page 51 and 52: or heat and superficial incision is
- Page 53 and 54: RecommendationsA. Preparation of th
- Page 55 and 56: 3. Mangram AJ, Horan TC, Pearson ML
- Page 57 and 58: Mild hypothermia increases blood lo
- Page 59 and 60: Perioperative Normothermia to Reduc
- Page 61 and 62: Priorities: Restoration of circulat
- Page 63 and 64: than 1.5 times control values but f
- Page 65 and 66: outcomes that may result from the u
- Page 67 and 68: Preoperative Preparation of the Pat
- Page 69 and 70: patients, or other patients who may
- Page 71: Obstruction can occur at the level
- Page 75 and 76: 8. Equipment suitable for emergency
- Page 77 and 78: 2. An evaluation for general clinic
- Page 79 and 80: educed anesthetic doses in the pres
- Page 81 and 82: anaesthesia reduced the risk of awa
- Page 83 and 84: Surviving Sepsis Campaign:Internati
- Page 85 and 86: Table 1. Determination of the quali
- Page 87 and 88: ooCulture other sites as clinically
- Page 89 and 90: o Epinepphrine, phenylephrine and v
- Page 91 and 92: oDo not use antithrombin therapy (1
- Page 93 and 94: ooUse either intermittent bolus sed
- Page 95 and 96: Consideration for limitation of sup
- Page 97 and 98: contraindicated (1B); avoiding rout
- Page 99 and 100: comparisons). During the same perio
- Page 101 and 102: had similar baseline characteristic
- Page 103 and 104: participating intensive-care units
- Page 105 and 106: Sprung CL, Annane D, Keh D, et al f
- Page 107 and 108: increased mechanical constraints pl
- Page 109 and 110: Megaprosthesis is the most attracti
- Page 111 and 112: complications are usually more rela
- Page 113 and 114: Springfield D (Eds), Surgery for bo
- Page 115 and 116: Infection in Limb Salvage Surgery :
- Page 117 and 118: considered to be two-stage revision
- Page 119 and 120: In contrast, articulating spacers p
- Page 121 and 122: The new endoprosthesis then was ins
- Page 123 and 124:
Diagnosis of InfectionThe diagnosis
- Page 125 and 126:
FDG-PET scanning had a positive pre
- Page 127 and 128:
10. Lord CF, Gebhardt MC, Tomford W
- Page 129 and 130:
31. Holzer G, Windhager R, Kotz R:
- Page 131 and 132:
Antibiotic Prophylaxis in Orthopaed
- Page 133 and 134:
124be wasteful, but potentially haz
- Page 135 and 136:
are less active than cefazolin agai
- Page 137 and 138:
3. There is no evidence to support
- Page 139 and 140:
ate from 2.7% to 1.3%, with a nonsi
- Page 141 and 142:
9. Saline irrigation of the wound c
- Page 143 and 144:
gentamicin-resistant organisms occu
- Page 145 and 146:
treatment of Staphylococcus aureus
- Page 147 and 148:
24. Nelson CL, Green RA, Porter RA,
- Page 149 and 150:
orthopedic wound infections. Acta O
- Page 151 and 152:
62. Masari BA, Duncan CP, Beauchamp
- Page 153 and 154:
involvement. several factors limit
- Page 155 and 156:
involvement in four of the 20 patie
- Page 157 and 158:
these were large and deep-seated so
- Page 160:
Section — IIHead and NeckContribu
- Page 163 and 164:
ManagementPrinciples The most impor
- Page 165 and 166:
4. Baker S.R. and Swanson N.A. Reco
- Page 167 and 168:
Osteoradionecrosis of the MandibleD
- Page 169 and 170:
Injury or dental extractions: Any s
- Page 171 and 172:
the patients responded to HBO alone
- Page 173 and 174:
9. Lyons A, Ghazali N. Osteoradione
- Page 175 and 176:
XerostomiaXerostomia is present in
- Page 177 and 178:
eduction in salivary pH, decreased
- Page 179 and 180:
170to those that received placebo.
- Page 181 and 182:
has been on techniques like IMRT, I
- Page 183 and 184:
8. Eisbruch A, Kim HM, Terrell JE,
- Page 185 and 186:
tonsillar region Int J Radiat Oncol
- Page 187 and 188:
Deterioration in the Quality of lif
- Page 189 and 190:
Toxicity gradingGrade 0 Grade 1 Gra
- Page 191 and 192:
Shown to decrease the severity and
- Page 193 and 194:
Problems Associated with Free Tissu
- Page 195 and 196:
- A flap with arterial blockade sho
- Page 197 and 198:
- Graft loss is commonly due to she
- Page 199 and 200:
References1. Microvascular free fla
- Page 201 and 202:
Recurrent Laryngeal Nerve (RLN)a. R
- Page 203 and 204:
When the EBSLN is damaged unilatera
- Page 205 and 206:
References1. Hermann M, Alk G, Roka
- Page 207 and 208:
Hypocalcemia FollowingThyroidectomy
- Page 209 and 210:
Prevention Thorough knowledge of th
- Page 211 and 212:
Annual Ophthalmologist evaluation f
- Page 213 and 214:
Risk factors Poor nutritional statu
- Page 215 and 216:
However, more often than not, inser
- Page 217 and 218:
Post-Laryngectomy TracheostomalSten
- Page 219 and 220:
Previous tracheostomy - no conclusi
- Page 221 and 222:
ChondroradionecrosisIntroduction an
- Page 223 and 224:
Concomitant chemotherapy may compou
- Page 225 and 226:
despite repeated negative biopsies
- Page 227 and 228:
Swallowing Dysfunction after Treatm
- Page 229 and 230:
Commonest dysfunction on MBS after
- Page 231 and 232:
Head rotated to the Improves vocal
- Page 233 and 234:
Hypothyroidism After Treatment forH
- Page 235 and 236:
References1) Long-term incidence of
- Page 237 and 238:
IV - Moderately severe dysfunction
- Page 239 and 240:
The functional status of the facial
- Page 241 and 242:
Frey’s SyndromeFrey’s syndrome
- Page 243 and 244:
The affected area is painted with i
- Page 245 and 246:
ReferencesManagement of Frey syndro
- Page 247 and 248:
Incidence:Depends upon the type of
- Page 249 and 250:
References1. Impact of shoulder com
- Page 251 and 252:
After every neck dissection, put th
- Page 253 and 254:
Algorithm for management of fistula
- Page 255 and 256:
PreventionThe main principle to pre
- Page 257 and 258:
difficult to appreciate. Characteri
- Page 259 and 260:
Operative Techniques include:1) End
- Page 261 and 262:
ooCisplatin, as single agent is the
- Page 263 and 264:
oooin many trials though the differ
- Page 265 and 266:
creatinine in males, 0.85 X (140-ag
- Page 267 and 268:
o Treatment of febrile neutropenia
- Page 269 and 270:
6. Seiwert TY, Salama JK and Vokes
- Page 272 and 273:
Complications of Abdomino-PelvicRad
- Page 274 and 275:
With these doses, the rate of necro
- Page 276 and 277:
sigmoid colon and rectum being in c
- Page 278 and 279:
complication rate of late rectal to
- Page 280 and 281:
after radiation therapy, bladder ir
- Page 282 and 283:
partial symptomatic resolution (P =
- Page 284 and 285:
increased with concurrent administr
- Page 286 and 287:
Suggested Reading:1. Hall EJ. Radio
- Page 288 and 289:
Radiation Induced Second MalignantN
- Page 290:
Table I: Risk of subsequent cancer
- Page 293 and 294:
traversed by a charged particle but
- Page 295 and 296:
modality treatment than RT alone (6
- Page 297 and 298:
vulva, anal canal and oropharynx) a
- Page 299 and 300:
Registries, 1973-2000. National Can
- Page 301 and 302:
Suggested Reading:1. Goldsby R, Bur
- Page 303 and 304:
adiation dose, and age at treatment
- Page 305 and 306:
dose. The excess relative risk for
- Page 307 and 308:
Radiation Induced Cardiac &Pulmonar
- Page 309 and 310:
Acute fibrinous pericarditis can pr
- Page 311 and 312:
Cardiac Morbidity & MortalityCardio
- Page 313 and 314:
effusion a mean of 150 days after t
- Page 315 and 316:
3. Mittal S, Berko B, Bavaria J, et
- Page 317 and 318:
Carver JR, Shapiro CL, Ng A, Jacobs
- Page 319 and 320:
RESULTS: In the total group, the ri
- Page 321 and 322:
For women diagnosed during 1993-200
- Page 323 and 324:
5.4%, SE 1.3, 2p=0.0002; overall mo
- Page 325 and 326:
PneumonitisThe clinical syndrome of
- Page 327 and 328:
Measurable end points of Pulmonary
- Page 329 and 330:
Useful radiation therapy planning p
- Page 331 and 332:
7. Rubin, P. Radiation toxicity: Qu
- Page 333 and 334:
profibrotic cytokines and molecules
- Page 335 and 336:
Graham MV, Purdy JA, Emami B, Harms
- Page 337 and 338:
Radiation MyelopathyIntroduction:Sp
- Page 339 and 340:
probably secondary to damage to the
- Page 341 and 342:
Time Course of Events: The onset ma
- Page 343 and 344:
since previous treatment, although
- Page 345 and 346:
tried 36 . Novel therapies as stem
- Page 347 and 348:
14. Abramson N, Cavanaugh PJ. Short
- Page 349 and 350:
MRI in differentiating spinal cord
- Page 351 and 352:
acceptability of the types of treat
- Page 353 and 354:
Radiation Induced Central NervousSy
- Page 355 and 356:
sensory or motor impairment. Numero
- Page 357 and 358:
Randomized trial in craniospinal ra
- Page 359 and 360:
RT to brain has been implicated as
- Page 361 and 362:
that there will be higher probabili
- Page 363 and 364:
Pseudo-progression needs to be diff
- Page 365 and 366:
CONCLUSION: The results document a
- Page 367 and 368:
Intelligence Score Chart (WISC), wh
- Page 369 and 370:
hypothesized ordering of groups in
- Page 371 and 372:
PATIENTS AND METHODS: Follow-up stu
- Page 373 and 374:
had undergone surgical procedure in
- Page 375 and 376:
which mirrors the increased inciden
- Page 377 and 378:
with population incidence rates thr
- Page 380:
Section — IVMedical OncologyContr
- Page 383 and 384:
Initial investigations - Complete b
- Page 385 and 386:
In low risk group, patient may rece
- Page 387 and 388:
trial design issues.1 Fluconazole s
- Page 389 and 390:
Duration of treatment may depend up
- Page 391 and 392:
Antibacterial agents-Overall risk E
- Page 393 and 394:
Gram positive DOSE Spectrum Comment
- Page 395 and 396:
Broad spectrum DOSE Spectrum Commen
- Page 397 and 398:
Broad spectrum DOSE Spectrum Commen
- Page 399 and 400:
Broad spectrum DOSE Spectrum Commen
- Page 401 and 402:
6. Bow EJ, Rotstein C, Noskin GA, e
- Page 403 and 404:
2. Delayed CINV: Nausea and vomitin
- Page 405 and 406:
Recommended Treatment OptionsAcute
- Page 407 and 408:
Evidence Based Management Guideline
- Page 409 and 410:
Management of refractory and breakt
- Page 411 and 412:
serotonin antagonist and dexamethas
- Page 413 and 414:
(no vomiting and no use of rescue t
- Page 415 and 416:
within 24 hours after the start of
- Page 417 and 418:
with age, often becoming clinically
- Page 419 and 420:
guidelines for screening & manageme
- Page 421 and 422:
Level Treatment Method of Frequency
- Page 423 and 424:
15. Wallace WH, Blacklay A, Eiser C
- Page 425 and 426:
health status domains were assessed
- Page 427 and 428:
of childhood cancer survivors is no
- Page 429 and 430:
Tumor Lysis SyndromeDefinition: Tum
- Page 431 and 432:
the grade of CTLS is defined by the
- Page 433 and 434:
Alkalinization for patients who wil
- Page 435 and 436:
deficiency should include a thoroug
- Page 437 and 438:
icarbonate and calcium should not b
- Page 439 and 440:
and should have ready access to ras
- Page 441 and 442:
Table 3 Risk Factors for Tumor Lysi
- Page 443 and 444:
Table 5 Recommended Rasburicase Dos
- Page 445 and 446:
1. Guidelines for the management of
- Page 447 and 448:
3. A randomized comparison between
- Page 449 and 450:
acid levels (6.4-16.8 mg/dl; median
- Page 451 and 452:
adiographic pattern is the hilar ly
- Page 453 and 454:
study involving 105 patients was 8.
- Page 455 and 456:
10. Sostman HD, Matthay RA, Putman
- Page 457 and 458:
distinguish between a normal GFR an
- Page 459 and 460:
of methotrexate induced nephropathy
- Page 461 and 462:
Bibliography1. De Jonge MJ, Verweij
- Page 463 and 464:
Mucositis and GastrointestinalToxic
- Page 465 and 466:
pathogenesis is similar for gastroi
- Page 467 and 468:
acceptable oral protocol include re
- Page 469 and 470:
Treatment of gastrointestinal mucos
- Page 471 and 472:
Hepatotoxicity ofChemotherapeutic A
- Page 473 and 474:
Capecitabine is the prodrug for 5-F
- Page 475 and 476:
Topotecan causes elevation of trans
- Page 477 and 478:
Daunorubicin: Reduce dose by 25% if
- Page 479 and 480:
9. Spriggs DR, Stopa E, Mayer RJ, e
- Page 481 and 482:
Dermatologic Toxicity of Antineopla
- Page 483 and 484:
ecause 15% of scalp hairs are not i
- Page 485 and 486:
5. Batchelor D. Hair and cancer che
- Page 487 and 488:
Anemia and Cancer - incidence, etio
- Page 489 and 490:
most accurate method for detecting
- Page 491 and 492:
levels, to define anemia and this m
- Page 493 and 494:
Darbopoietin Vs Epoetin Alfa: Is Th
- Page 495 and 496:
arm (2.4 g/dl) compared to patients
- Page 497 and 498:
12. Yellen SB, Cella DF, Webster K,
- Page 499 and 500:
490NOTES
- Page 501:
NOTES